Reardon Andrew
SEC CIK 1950232 · EDGAR
BoughtSold
Companies
| Ticker | Company | Title | Holding | Bought | Sold | Trades | First | Last |
|---|---|---|---|---|---|---|---|---|
| LGND | LIGAND PHARMACEUTICALS INC | See Remarks | 36.5K | — | $10.20M | 40 | 2022-11-30 | 2026-09-03 |
Most active insiders at LGND, 12 months
| # | Insider | Title | Bought | Sold |
|---|---|---|---|---|
| 1 | Espinoza Octavio | CFO | — | $13.03M |
| 2 | Reardon Andrew | CLO, Sec | — | $8.77M |
| 3 | Haas Jason | Dir | — | $3.74M |
| 4 | LAMATTINA JOHN L | Dir | — | $2.44M |
| 5 | Gray Nancy Ryan | Dir | — | $1.35M |
| 6 | Aryeh Jason | Dir | — | $1.25M |
| 7 | KOZARICH JOHN W | Dir | — | $1.20M |
| 8 | Sabba Stephen L | Dir | — | $1.16M |
| 9 | Zimmermann Martine | Dir | — | $342.0K |
| 10 | Davis Todd C | CEO, Dir | — | — |
Transactions 40
| X | Filed | Traded | Ticker | Company | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MT | 2026-09-08 18:34 | 2026-09-03 | LGND | LIGAND PHARMACEUTICALS INC | Reardon Andrew | CLO, Sec | S - Sale | $286.09 | -5,000 | 36.5K | -12% | -$1.43M |
| DT | 2026-08-04 18:42 | 2026-08-03 | LGND | LIGAND PHARMACEUTICALS INC | Reardon Andrew | CLO, Sec | M - OptEx | $52.27 | +5,000 | 46.5K | +12% | +$261.4K |
| DMT | 2026-08-04 18:42 | 2026-08-03 | LGND | LIGAND PHARMACEUTICALS INC | Reardon Andrew | CLO, Sec | S - Sale+OE | $288.99 | -5,000 | 41.5K | -11% | -$1.44M |
| DT | 2026-07-06 17:11 | 2026-06-30 | LGND | LIGAND PHARMACEUTICALS INC | Reardon Andrew | CLO, Sec | J - Other | $160.71 | +132 | 41.5K | +0.3% | +$21.2K |
| DT | 2026-07-06 17:11 | 2026-07-01 | LGND | LIGAND PHARMACEUTICALS INC | Reardon Andrew | CLO, Sec | M - OptEx | $52.27 | +5,000 | 46.5K | +12% | +$261.4K |
| DMT | 2026-07-06 17:11 | 2026-07-01 | LGND | LIGAND PHARMACEUTICALS INC | Reardon Andrew | CLO, Sec | S - Sale+OE | $313.28 | -5,000 | 41.5K | -11% | -$1.57M |
| DT | 2026-06-02 18:22 | 2026-06-01 | LGND | LIGAND PHARMACEUTICALS INC | Reardon Andrew | CLO, Sec | M - OptEx | $52.27 | +5,000 | 46.4K | +12% | +$261.4K |
| DMT | 2026-06-02 18:22 | 2026-06-01 | LGND | LIGAND PHARMACEUTICALS INC | Reardon Andrew | CLO, Sec | S - Sale+OE | $227.06 | -5,000 | 41.4K | -11% | -$1.14M |
| DT | 2026-05-04 20:20 | 2026-05-01 | LGND | LIGAND PHARMACEUTICALS INC | Reardon Andrew | CLO, Sec | M - OptEx | $52.27 | +5,000 | 46.4K | +12% | +$261.4K |
| DMT | 2026-05-04 20:20 | 2026-05-01 | LGND | LIGAND PHARMACEUTICALS INC | Reardon Andrew | CLO, Sec | S - Sale+OE | $231.31 | -5,000 | 41.4K | -11% | -$1.16M |
| DT | 2026-04-02 18:56 | 2026-04-01 | LGND | LIGAND PHARMACEUTICALS INC | Reardon Andrew | CLO, Sec | M - OptEx | $52.27 | +5,000 | 46.4K | +12% | +$261.4K |
| DMT | 2026-04-02 18:56 | 2026-04-01 | LGND | LIGAND PHARMACEUTICALS INC | Reardon Andrew | CLO, Sec | S - Sale+OE | $201.24 | -5,000 | 41.4K | -11% | -$1.01M |
| D | 2026-03-27 | 2026-03-02 | LGND | LIGAND PHARMACEUTICALS INC | Reardon Andrew | CLO, Sec | A - Grant | $0.00 | +4,513 | 41.4K | +12% | $0 |
| DM | 2026-03-06 | 2026-03-04 | LGND | LIGAND PHARMACEUTICALS INC | Reardon Andrew | CLO, Sec | S - Sale+OE | $206.35 | -5,000 | 41.1K | -11% | -$1.03M |
| D | 2026-03-06 | 2026-03-04 | LGND | LIGAND PHARMACEUTICALS INC | Reardon Andrew | CLO, Sec | M - OptEx | $52.27 | +5,000 | 41.9K | +14% | +$261.4K |
| M | 2026-02-18 | 2026-02-14+ | LGND | LIGAND PHARMACEUTICALS INC | Reardon Andrew | CLO, Sec | F - Tax | $183.83 | -9,680 | 34.5K | -22% | -$1.78M |
| M | 2026-02-18 | 2026-02-14 | LGND | LIGAND PHARMACEUTICALS INC | Reardon Andrew | CLO, Sec | A - Grant | $0.00 | +15.7K | 43.3K | +57% | $0 |
| 2025-08-12 | 2025-08-10 | LGND | LIGAND PHARMACEUTICALS INC | Reardon Andrew | CLO, Sec | F - Tax | $150.06 | -1,325 | 30.8K | -4% | -$198.8K | |
| 2025-07-02 | 2025-06-30 | LGND | LIGAND PHARMACEUTICALS INC | Reardon Andrew | CLO, Sec | J - Other | $91.08 | +233 | 32.1K | +0.7% | +$21.2K | |
| 2025-06-24 | 2025-06-23 | LGND | LIGAND PHARMACEUTICALS INC | Reardon Andrew | CLO, Sec | S - Sale | $114.08 | -500 | 31.9K | -2% | -$57.0K | |
| 2025-06-12 | 2025-06-10 | LGND | LIGAND PHARMACEUTICALS INC | Reardon Andrew | CLO, Sec | S - Sale | $114.54 | -500 | 32.4K | -2% | -$57.3K | |
| 2025-06-02 | 2025-05-15 | LGND | LIGAND PHARMACEUTICALS INC | Reardon Andrew | CLO, Sec | S - Sale | $104.00 | -1,000 | 32.9K | -3% | -$104.0K | |
| 2025-06-02 | 2024-08-10 | LGND | LIGAND PHARMACEUTICALS INC | Reardon Andrew | CLO, Sec | F - Tax | $100.16 | -897 | 21.6K | -4% | -$89.8K | |
| D | 2025-03-06 | 2025-03-04 | LGND | LIGAND PHARMACEUTICALS INC | Reardon Andrew | CLO, Sec | A - Grant | $0.00 | +6,415 | 34.8K | +23% | $0 |
| M | 2025-02-19 | 2025-02-14+ | LGND | LIGAND PHARMACEUTICALS INC | Reardon Andrew | CLO, Sec | F - Tax | $120.00 | -6,523 | 29.2K | -18% | -$782.8K |
| M | 2025-02-19 | 2025-02-14 | LGND | LIGAND PHARMACEUTICALS INC | Reardon Andrew | CLO, Sec | A - Grant | $0.00 | +12.4K | 29.5K | +72% | $0 |
| D | 2024-09-25 | 2024-09-23 | LGND | LIGAND PHARMACEUTICALS INC | Reardon Andrew | CLO, Sec | M - OptEx | $52.27 | +2,000 | 24.5K | +9% | +$104.5K |
| D | 2024-09-25 | 2024-09-23 | LGND | LIGAND PHARMACEUTICALS INC | Reardon Andrew | CLO, Sec | S - Sale+OE | $99.60 | -2,000 | 22.5K | -8% | -$199.2K |
| D | 2024-08-30 | 2024-08-28 | LGND | LIGAND PHARMACEUTICALS INC | Reardon Andrew | CLO, Sec | S - Sale+OE | $106.39 | -1,500 | 22.5K | -6% | -$159.6K |
| D | 2024-08-30 | 2024-08-28 | LGND | LIGAND PHARMACEUTICALS INC | Reardon Andrew | CLO, Sec | M - OptEx | $52.27 | +1,500 | 24.0K | +7% | +$78.4K |
| 2024-07-02 | 2024-06-28 | LGND | LIGAND PHARMACEUTICALS INC | Reardon Andrew | CLO | J - Other | $60.71 | +329 | 22.5K | +1% | +$20.0K | |
| D | 2024-05-13 | 2024-05-09 | LGND | LIGAND PHARMACEUTICALS INC | Reardon Andrew | CLO | M - OptEx | $52.27 | +10.0K | 32.2K | +45% | +$522.7K |
| D | 2024-05-13 | 2024-05-09 | LGND | LIGAND PHARMACEUTICALS INC | Reardon Andrew | CLO | S - Sale+OE | $83.04 | -10.0K | 22.2K | -31% | -$830.4K |
| D | 2024-02-29 | 2024-02-27 | LGND | LIGAND PHARMACEUTICALS INC | Reardon Andrew | CLO | A - Grant | $0.00 | +7,208 | 22.2K | +48% | $0 |
| 2024-02-16 | 2024-02-15 | LGND | LIGAND PHARMACEUTICALS INC | Reardon Andrew | CLO | F - Tax | $74.65 | -593 | 15.0K | -4% | -$44.3K | |
| 2024-01-04 | 2023-12-29 | LGND | LIGAND PHARMACEUTICALS INC | Reardon Andrew | CLO | J - Other | $60.71 | +179 | 15.6K | +1% | +$10.9K | |
| 2023-08-14 | 2023-08-10 | LGND | LIGAND PHARMACEUTICALS INC | Reardon Andrew | CLO | F - Tax | $68.73 | -897 | 15.4K | -6% | -$61.7K | |
| 2023-03-28 | 2023-03-24 | LGND | LIGAND PHARMACEUTICALS INC | Reardon Andrew | See Remarks | S - Sale | $69.92 | -300 | 16.3K | -2% | -$21.0K | |
| D | 2023-02-27 | 2023-02-23 | LGND | LIGAND PHARMACEUTICALS INC | Reardon Andrew | See Remarks | A - Grant | $0.00 | +5,668 | 16.6K | +52% | $0 |
| 2022-12-01 | 2022-11-30 | LGND | LIGAND PHARMACEUTICALS INC | Reardon Andrew | See Remarks | F - Tax | $72.90 | -1,073 | 10.9K | -9% | -$78.2K |
Purchase Sale Sale after option exercise All abbreviations